Harvard dominates in US News medical school rankings

Of the nine categories included in the 2019 Best Medical Schools rankings released by U.S. News and World Report, Harvard University either tied or placed alone at No. 1 in eight of them—the sole exception being the primary care category.

Harvard topped the rankings in the following categories: research, anesthesiology, radiology, psychiatry, internal medicine (tied with John Hopkins University), pediatrics (tied with the University of Pennsylvania), surgery and obstetrics & gynecology. The school was No. 12 in the primary care category, which placed the University of North Carolina at No. 1.

The rankings were released as part of the annual U.S. News rankings on the best graduate schools. The new lists did reflect a change in the methodology which decreased the importance of a school’s reputation in the research rankings.

“To better account for all the research activity conducted at medical schools, U.S. News added four new factors to measure nonfederal research grants and non-National Institutes of Health federal research grants in the medical schools research ranking. Simultaneously, U.S. News decreased the weight of reputation by 10 percentage points in this ranking,” the report said.

Here are the top five schools in each of the nine categories:

Research

1.       Harvard University

2.       John Hopkins University

3.       (tie) New York University

3.       (tie) Stanford University

5.       University of California, San Francisco

Primary Care

1.       University of North Carolina, Chapel Hill

2.       University of California, San Francisco

3.       University of Washington

4.       University of California, Los Angeles

5.       (tie) Baylor College of Medicine

5.       (tie) Oregon Health and Science University

Anesthesiology

1.       Harvard University

2.       University of California, San Francisco

3.       John Hopkins University

4.       University of Pennsylvania

5.       Duke University

Radiology

1.       Harvard

2.       (tie) John Hopkins University

2.       (tie) University of California, San Francisco

4.       University of Pennsylvania

5.       Washington University in St. Louis

Psychiatry

1.       Harvard University

2.       Columbia University

3.       University of Pennsylvania

4.       Yale University

5.       (tie) John Hopkins University

5.       (tie) University of California, San Francisco

Internal Medicine

1.       (tie) Harvard University

1.       (tie) John Hopkins University

3.       University of California, San Francisco

4.       University of Pennsylvania

5.       Duke University

Pediatrics

1.       (tie) Harvard University

1.       (tie) University of Pennsylvania

3.       University of Cincinnati  

4.       University of Colorado

5.       (tie) John Hopkins University

5.       University of California, San Francisco

Surgery

1.       Harvard University

2.       John Hopkins University

3.       University of Pennsylvania

4.       University of California, San Francisco

5.       Duke University

Obstetrics & Gynecology

1.       Harvard University

2.       University of California, San Francisco

3.       John Hopkins University

4.       University of Michigan, Ann Arbor

       University of Pennsylvania

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.